Trial · NCT03735979

Multi-arm Optimization of Stroke Thrombolysis

NCT03735979, Phase 3, Completed, Washington University School of Medicine; results first posted 2024-11-19

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Multi-arm Optimization of Stroke Thrombolysis. Trials, record NCT03735979. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03735979

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Multi-arm Optimization of Stroke Thrombolysis
NCT number: NCT03735979
Status: Completed
Phases: Phase 3
Enrollment: 514 participants, actual
Lead sponsor: Washington University School of Medicine
Conditions: Acute Ischemic Stroke
Interventions: Argatroban, Eptifibatide, Placebo
First posted: 2018-11-08
Last updated: 2025-02-07
Results first posted: 2024-11-19

Source ClinicalTrials.gov

Registered outcomes13

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	90-day Utility Weighted Modified Rankin Scores (UW-mRS)	90 days after randomization	The modified Rankin scale is a 7 point ordinal scale ranging from 0="no symptoms" to 6="death" . For the primary analysis, the scale was analyzed with patient-centered utility weights. We assigned the following utility weights to the seven levels: 10, 9.1,, 7.6, 6.5, 3.3, 0, 0 (with higher scores indicating a better outcome).
Secondary	Percentage of Participants With NIHSS Less Than or Equal to 2 at 24 Hours	24 hours after randomization	National Institute of Health Stroke Scale (NIHSS) scores range from 0 to 42, with higher scores indicating worse neurologic deficit. This is a dichotomous analysis with a cutpoint of 0,1,2 defining the event.
Secondary	Change From Baseline to 24-hour NIHSS	24 hours after randomization	National Institute of Health Stroke Scale (NIHSS) scores range from 0 to 42, with higher scores indicating worse neurologic deficit.
Secondary	Percentage of Participants With 90-day mRS 0 or 1 (or Return to Their Historical mRS)	90 days after randomization	The modified Rankin scale (mRS) is a 7 point scale ranging from 0="no symptoms" to 6="death" where lower scores are better outcomes. For patients with a pre-stroke mRS of greater than 0 or 1, these patients had to return to their historical (pre-stroke) value to be counted as a success.
Secondary	Percentage of Participants With 90-day mRS 0, 1 or 2 (or Return to Their Historical mRS)	90 days after randomization	modified Rankin scale is a 7 point scale ranging from 0="no symptoms" to 6="death" where lower scores are better outcomes.
Secondary	90-day mRS	90 days after randomization	modified Rankin scale is a 7 point ordinal scale ranging from 0="no symptoms at all" to 6="death" where lower scores are better outcomes.
Secondary	90-day EQ-5D	90 days after randomization	EuroQol Five-Dimension (EQ-5D) is a measure of health-related quality of life ranging from -0.59 to 1 where 1 is the best possible health state.
Secondary	Pre-thrombectomy Modified TICI Score of 2B.	baseline	The modified thrombolysis in cerebral infarction (TICI) score prior to endovascular thrombectomy procedure. The modified pre-thrombectomy TICI score is a 4 point scale with possible values of 0, 1, 2A, and 2B. The values are defined as follows: 0=No flow, 1=Penetration without distal branch filling, 2A=\<50% partial reperfusion, and 2B=50%-99% partial reperfusion.
Secondary	Post-thrombectomy Modified TICI Score of 2B or 3	baseline	The modified thrombolysis in cerebral infarction (TICI) score prior to endovascular thrombectomy procedure. The modified post-thrombectomy TICI score is a 5 point scale with possible values of 0, 1, 2A, 2B, 3. The values are defined as follows: 0=No flow, 1=Penetration without distal branch filling, 2A=\<50% partial reperfusion, 2B=50%-99% partial reperfusion, and 3=Completed reperfusion
Other	Symptomatic Intracranial Hemorrhage Within 36 Hours (Primary Safety Outcome)	36 hours after randomization	Type 2 parenchymal hemorrhage or a parenchymal hemorrhage remote from the area of infarction with neurologic deterioration (defined as an increase of ≥4 points in the NIHSS score)within 36 hours after randomization.

1 to 10 of 13Source ClinicalTrials.gov

See all 13 registered outcomes

Outcomes13

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	90-day Utility Weighted Modified Rankin Scores (UW-mRS)	90 days after randomization	Intention-to-treat	score on a scale	MEAN
SECONDARY	Percentage of Participants With NIHSS Less Than or Equal to 2 at 24 Hours	24 hours after randomization		Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Change From Baseline to 24-hour NIHSS	24 hours after randomization		units on a scale	MEAN
SECONDARY	Percentage of Participants With 90-day mRS 0 or 1 (or Return to Their Historical mRS)	90 days after randomization	Intention-to-treat sample	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Percentage of Participants With 90-day mRS 0, 1 or 2 (or Return to Their Historical mRS)	90 days after randomization	Intention-to-treat	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	90-day mRS	90 days after randomization	Intention-to-treat	units on a scale	MEDIAN
SECONDARY	90-day EQ-5D	90 days after randomization		score on a scale	MEAN
SECONDARY	Pre-thrombectomy Modified TICI Score of 2B.	baseline	Only participants that received endovascular thrombectomy are analyzed for this outcome.	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Post-thrombectomy Modified TICI Score of 2B or 3	baseline	Only participants that received endovascular thrombectomy are analyzed for this outcome.	Participants	COUNT_OF_PARTICIPANTS
OTHER_PRE_SPECIFIED	Symptomatic Intracranial Hemorrhage Within 36 Hours (Primary Safety Outcome)	36 hours after randomization	Participants that took any amount of study drug (safety sample)	Participants	COUNT_OF_PARTICIPANTS

1 to 10 of 13Source ClinicalTrials.gov

See all 13 outcomes

Results by group39

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
90-day Utility Weighted Modified Rankin Scores (UW-mRS)	Argatroban	5.2	Standard Deviation 3.7	score on a scale
90-day Utility Weighted Modified Rankin Scores (UW-mRS)	Eptifibatide	6.3	Standard Deviation 3.2	score on a scale
90-day Utility Weighted Modified Rankin Scores (UW-mRS)	Placebo	6.8	Standard Deviation 3.0	score on a scale
Percentage of Participants With NIHSS Less Than or Equal to 2 at 24 Hours	Argatroban	14		Participants
Percentage of Participants With NIHSS Less Than or Equal to 2 at 24 Hours	Eptifibatide	84		Participants
Percentage of Participants With NIHSS Less Than or Equal to 2 at 24 Hours	Placebo	89		Participants
Change From Baseline to 24-hour NIHSS	Argatroban	-5.1	Standard Deviation 9.3	units on a scale
Change From Baseline to 24-hour NIHSS	Eptifibatide	-6.1	Standard Deviation 8.4	units on a scale
Change From Baseline to 24-hour NIHSS	Placebo	-6.3	Standard Deviation 6.8	units on a scale
Percentage of Participants With 90-day mRS 0 or 1 (or Return to Their Historical mRS)	Argatroban	14		Participants

1 to 10 of 39Source ClinicalTrials.gov

See all 39 results by group

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Argatroban	59
Overall Study	STARTED	Eptifibatide	227
Overall Study	STARTED	Placebo	228
Overall Study	COMPLETED	Argatroban	56
Overall Study	COMPLETED	Eptifibatide	210
Overall Study	COMPLETED	Placebo	212
Overall Study	NOT COMPLETED	Argatroban	3
Overall Study	NOT COMPLETED	Eptifibatide	17
Overall Study	NOT COMPLETED	Placebo	16

Source ClinicalTrials.gov

Adverse events90

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Anaemia	Blood and lymphatic system disorders	Argatroban	2	59	2
other	Anaemia	Blood and lymphatic system disorders	Eptifibatide	1	227	1
other	Anaemia	Blood and lymphatic system disorders	Placebo	3	228	3
other	Atrial fibrillation	Cardiac disorders	Argatroban	2	59	2
other	Atrial fibrillation	Cardiac disorders	Eptifibatide	5	227	5
other	Atrial fibrillation	Cardiac disorders	Placebo	3	228	3
other	Urinary tract infection	Infections and infestations	Argatroban	0	59	0
other	Urinary tract infection	Infections and infestations	Eptifibatide	3	227	3
other	Urinary tract infection	Infections and infestations	Placebo	2	228	2
other	Coronavirus test positive	Infections and infestations	Argatroban	0	59	0

1 to 10 of 90Source ClinicalTrials.gov

See all 90 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Argatroban	13	54
Total, all-cause mortality	Eptifibatide	25	212
Total, all-cause mortality	Placebo	17	217
Total, other adverse events	Argatroban	12	59
Total, other adverse events	Eptifibatide	42	227
Total, other adverse events	Placebo	33	228
Total, serious adverse events	Argatroban	26	59
Total, serious adverse events	Eptifibatide	85	227
Total, serious adverse events	Placebo	78	228

Source ClinicalTrials.gov

Papers6

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
33297893	DERIVED	PubMed
37256980	DERIVED	PubMed
39231343	DERIVED	PubMed
40123511	DERIVED	PubMed
40824660	DERIVED	PubMed
41071964	DERIVED	PubMed

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
U01NS100699	Multi-arm Optimization of Stroke Thrombolysis (MOST) Stroke Trial	ADEOYE, OPEOLU M; BARRETO, ANDREW D; BRODERICK, JOSEPH PAUL; DERDEYN, COLIN PIETER; GROTTA, JAMES C	WASHINGTON UNIVERSITY	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE	2018 to 2021

Source NIH RePORTER

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT03735979

GET https://conductscience.org/api/trials/v1/NCT03735979/results?page=2

API reference For AI assistants